Clinical trial
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable…
NCT00216476 · Janssen-Cilag International NV, Industry · Completed
Key facts
| NCT number | NCT00216476 |
|---|---|
| Title | A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
| Official title | CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness |
| Lead sponsor | Janssen-Cilag International NV, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine |
| Enrollment | 753 |
| Start date | Oct 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 16, 2014 |
| Countries | Austria, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Israel and 12 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: